CLDX
HealthcareCelldex Therapeutics, Inc. · Biotechnology · $2B
What is Celldex Therapeutics, Inc.?
Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on developing monoclonal and bispecific antibodies targeting inflammatory diseases and cancer. Headquartered in Hampton, New Jersey, the company is advancing a pipeline of antibody-based therapeutics through clinical trials.
Celldex generates no commercial revenue yet — its business model centers on advancing proprietary drug candidates through clinical development. The company funds operations through capital raises and collaboration agreements, including partnerships with Amgen and academic institutions such as Yale University and the University of Southampton. Revenue, if achieved, would come from licensing deals, milestone payments, or eventual commercialization of approved therapies.
Celldex Therapeutics was incorporated in 1983 and is headquartered in Hampton, New Jersey.
- CDX-0159 — a monoclonal antibody targeting the KIT receptor for inflammatory diseases
- CDX-1140 — a CD40 agonist antibody designed to activate immune responses against cancer
- CDX-527 — a bispecific antibody coupling PD-L1 blockade with CD27 costimulation for anti-tumor T cell activation
Is CLDX a Good Stock to Buy?
UQS Score rates CLDX as Poor overall, reflecting the significant challenges typical of a pre-commercial clinical-stage biotech.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's financial structure carries a degree of resilience compared to its developmental stage peers.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products and depends on clinical trial outcomes. Valuation is rated Elevated, meaning the current price reflects considerable optimism about pipeline success.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CLDX pay dividends?
No — Celldex Therapeutics, Inc. does not currently pay a dividend.
Celldex does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding research, clinical trials, and pipeline advancement. Investors in CLDX are positioned for potential long-term value through drug development outcomes rather than income distributions.
When does CLDX report earnings?
Celldex Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, clinical trial progress, and operating expenses rather than traditional revenue or profit metrics. Pipeline updates and trial readouts tend to be the most market-moving disclosures.
For the most recent quarter's results and pipeline updates, visit Celldex Therapeutics' investor relations page directly.
CLDX Price History
+22.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Celldex Therapeutics, Inc.?
Based on Celldex Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CLDX Long-term Outlook
The fundamental outlook for CLDX is shaped by its clinical pipeline rather than near-term financial performance. With Growth rated Weak and Valuation rated Elevated, the stock appears to price in meaningful pipeline success that has yet to materialize. Risk rated Good provides some reassurance about financial stability, but the path to value creation remains contingent on clinical trial outcomes.
Growth drivers
- Potential clinical advancement of CDX-0159 in inflammatory disease indications
- Collaboration milestones and licensing opportunities from academic and industry partnerships
- Expansion of the oncology pipeline through CDX-1140 and CDX-527 trial data
Key risks
- Clinical trial failure — any pipeline setback could significantly impair the investment thesis
- Elevated valuation leaves limited margin of safety if trial timelines extend
- Ongoing cash consumption without commercial revenue creates dilution risk over time
CLDX vs Peers
Celldex operates in a competitive clinical-stage biotech landscape alongside other companies developing novel biologics and antibody-based therapies.
Sarepta focuses on genetic medicines for rare neuromuscular diseases, giving it a distinct therapeutic focus and a more advanced commercial presence than Celldex.
Adaptive leverages immune medicine and T-cell biology through a platform approach, differentiating itself with diagnostic and therapeutic applications across oncology and autoimmune disease.
Definium is an earlier-stage company pursuing targeted therapeutic development, competing in a similar pre-commercial biotech space.
Frequently Asked Questions
What does Celldex Therapeutics do?
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibodies. Its pipeline targets inflammatory diseases and various cancers, with programs designed to modulate immune pathways. The company has no approved products and funds operations through capital markets and collaboration agreements.
Does CLDX pay dividends?
No, Celldex does not pay a dividend. Pre-commercial biotechs typically reinvest all capital into research and clinical development. Investors in CLDX are betting on pipeline success rather than seeking income from the stock.
When does CLDX report earnings?
Celldex reports on a standard quarterly schedule. Because it is pre-revenue, the most important disclosures are clinical trial updates and cash position rather than traditional earnings figures. Check the company's investor relations page for the latest reporting schedule.
Is CLDX a good stock to buy?
UQS Score rates CLDX as Poor overall. Quality, Moat, and Growth are all Weak, while Valuation is Elevated — a combination that signals meaningful risk relative to current pricing. Risk is the one pillar showing relative strength. The full breakdown is available to Pro members.
Is CLDX overvalued?
UQS Score rates CLDX's Valuation as Elevated, suggesting the market is pricing in significant pipeline success that has not yet been demonstrated. For a pre-revenue company with Weak Growth and Moat ratings, this creates a challenging risk-reward profile at current levels.
How does CLDX compare to its competitors?
Celldex competes in the clinical-stage biotech space alongside companies like Sarepta Therapeutics and Adaptive Biotechnologies. Unlike Sarepta, which has reached commercial-stage products, Celldex remains fully pre-revenue. UQS Score's side-by-side comparisons are available on each competitor's page.
What is CLDX's market cap bracket?
Celldex Therapeutics is classified as a mid-cap company. This places it above the micro- and small-cap tiers common among early clinical biotechs, reflecting the market's recognition of its pipeline potential despite the absence of commercial revenue.
Who founded Celldex Therapeutics?
Celldex Therapeutics was incorporated in 1983 and has evolved through multiple strategic transformations over the decades. Detailed founding history and leadership background are publicly available through the company's official filings and investor relations materials.
Is CLDX a long-term quality investment?
As a long-term quality indicator, UQS Score rates CLDX as Poor. Weak scores across Quality, Moat, and Growth suggest the company has not yet demonstrated the durable business characteristics associated with long-term compounders. Clinical success could change this profile materially over time.
What is the main competitive advantage of Celldex Therapeutics?
Celldex's differentiation lies in its proprietary antibody platforms — particularly its bispecific antibody technology and CD40 agonist approach. These are novel mechanisms with limited direct competition. However, UQS Score currently rates Moat as Weak, reflecting the early-stage and unproven commercial nature of these assets.
Unlock Full CLDX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access the underlying financial metrics driving each pillar rating
- ✓Compare CLDX side-by-side with Sarepta, Adaptive Biotechnologies, and other peers
- ✓Screen for higher-quality biotech alternatives using UQS preset filters
- ✓Track CLDX score changes as new clinical and financial data emerges
Pro Analysis
CLDX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 22.3 | 0.0 | 14.0 | 38.3 | 74.3 | 0.0 | +0.1 |
| May 8, 2026 | 22.2 | 0.0 | 14.0 | 38.3 | 73.8 | 0.0 | -0.1 |
| Apr 2, 2026 | 22.3 | 0.0 | 14.0 | 38.3 | 74.4 | 0.0 | — |
CLDX — Pillar Breakdown
Quality
— 0.0/100 (25%)Celldex Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 38.3/100 (20%)Celldex Therapeutics, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.3/100 (15%)Celldex Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Celldex Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Celldex Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CLDX.
Score Composition
Financial Data
More Stock Analysis
How is the CLDX UQS Score Calculated?
The UQS (Unified Quality Score) for Celldex Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Celldex Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Celldex Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.